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Objective: To determine whether characteristics of glucose dynamics are reﬂections of b-cell function or
rather of inadequate diabetes control.
Materials/methods: We analyzed historical liquid meal tolerance test (LMTT) and continuous glucose
monitoring (CGM) data, which had been obtained from 56 non-insulin treated type 2 diabetic out-
patients during withdrawal of antidiabetic drugs. Computed CGM parameters included detrended ﬂuc-
tuation analysis (DFA)-based indices, autocorrelation function exponent, mean amplitude of glycemic
excursions (MAGE), glucose SD, and measures of glycemic exposure. The LMTT-based disposition index
(LMTT-DI) calculated from the ratio of the area-under-the-insulin-curve to the area-under-the-glucose-
curve and Matsuda index was used to assess relationships among b-cell function, glucose proﬁle
complexity, autocorrelation function, and glycemic variability.
Results: The LMTT-DI was inverse linearly correlated with the short-range a1 and long-range scaling
exponent a2 (r ¼ 0.275 and 0.441, respectively, p < 0.01) such that lower glucose complexity was
associated with better preserved insulin reserve, but it did not correlate with the autocorrelation decay
exponent g. By contrast, the LMTT-DI was strongly correlated with MAGE and SD (r ¼ 0.625 and 0.646,
both p < 0.001), demonstrating a curvilinear relationship between b-cell function and glycemic vari-
ability. On stepwise regression analyses, the LMTT-DI emerged as an independent contributor,
explaining 20, 38, and 47% (all p < 0.001) of the variance in the long-range DFA scaling exponent,
MAGE, and hemoglobin A1C, respectively, whereas insulin sensitivity failed to contribute
independently.
Conclusions: Loss of complexity and increased variability in glucose proﬁles are associated with declining
b-cell reserve and worsening glycemic control.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.area under the curve; CGM, continuous glucose monitoring; Cp, C-peptide; DFA, detrended ﬂuctuation analysis; LMTT,
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Regulation of glucose concentration is a complex process that
involves several hormones among which insulin plays a prominent
role. The failing glucoregulation observed in the development of
diabetes signals declining b-cell reserve and may be assessed by
measurement of glucose dynamics, utilizing indices of glycemic
variability and different techniques of time-series analysis. Using
detrended ﬂuctuation analysis (DFA), Churruca et al. [1] and
Yamamoto et al. [2] described a loss of glucose proﬁle complexity in
the progression from normoglycemia to impaired glucose tolerance
to overt diabetes, and Ogata et al. [3] have reported that increasing
long-range DFA scaling exponents reﬂect abnormalities in glycemic
control. Moreover, Khovanova et al. [4] have recently shown that
the dynamics of glucose proﬁles can be deﬁned by three comple-
mentary characteristics: nonstationarity (DFA exponent a), linear
predictability (autocorrelation coefﬁcient g), and amplitude of
variation (glucose SD). However, it is not known whether changes
in glucose proﬁle dynamics are primarily dependent on exogenous
or endogenous factors.
Previous reports [5,6], Rodbard’s recent interpretations [7], and
own data [8,9] support the assumption that b-cell dysfunction might
be the underlying pathophysiologic basis of glycemic variability.
Furthermore, in a study of patientswith early type 2 diabetes Kramer
et al. [10] found that improvement of b-cell function was the key
determinant of the reduction in glycemic variability in response to
short-term intensive insulin therapy. These observations led us to
infer that the b-cell reserve may predict changes in various dynamic
parameters of glucose proﬁles. However, whether the inherent
structure in glucose proﬁles mirrors certain aspects of b-cell
dysfunction relative to insulin resistance is currently unknown, as is
the association among measures of glucose proﬁle dynamics and re-
sidual b-cell capacity. Given the increasing use of continuous glucose
monitoring (CGM) in glycemic control, it appears essential to reveal
such relationships for qualitatively better therapeutic capabilities, e.g.
timelyadjustmentof therapyappropriate to thecurrentb-cell reserve.
Achievementof glycemic stability andmetabolicﬂexibility inpatients
with type 2 diabetes by early therapeutic intervention appears to be a
conceptual model to prevent loss of residual b-cell function. We hy-
pothesize that dynamical changes in glucose proﬁles reﬂect under-
lying functional aspects of the failing b-cell during worsening of
glycemic control. To address this issue, we used glucose complexity
measures, autocorrelation function, and glycemic variability metrics
for analysis of glucose dynamics and the validated liquid meal toler-
ance test-based disposition index (LMTT-DI) for evaluation of b-cell
function. Like the oral glucose tolerance test-basedmeasure of insulin
secretion and insulin sensitivity [11], the LMTT-DI has been shown to
represent an accurate, integrated measure of b-cell function [12].
Thus, this index appeared to be useful in the current study for
assessing b-cell function in relation to glucose proﬁle characteristics.Methods
The present investigation used historical data, which were ob-
tained in an earlier study during withdrawal of diabetes therapy in
outpatients with type 2 diabetes mellitus [8]. Retrospective analysis
of anonymized ambulatory CGM proﬁles (MiniMed Solution Soft-
ware, Medtronic MiniMed) and LMTT data was performed, using a
validated b-cell function index and established measures of glucose
proﬁle dynamics. Glucose proﬁles with a minimum of four blood
glucose meter calibrations per day and a mean duration of 60-h
continuous monitoring had been downloaded and used for calcu-
lations of glucose proﬁle parameters. Data not meeting strict val-
idity criteria of the manufacturer were excluded.Subjects and study procedure
The original study had received ethical approval and, before
inclusion, all study participants provided their written informed
consent. Thus, no further approval was required for this retro-
spective data analysis. The characteristics of the patient cohort and
the study procedure have been described in detail elsewhere [8]. In
brief, before commencement of any of the study procedures anti-
diabetic medication had been withdrawn and substituted with
placebo for 8 days to allow for their pharmacological effects to
dissipate. Five patients who had been taking thiazolidinediones
(TZDs) were excluded from the study. After a 12-h overnight fast,
patients were given a standardized 500 mL liquid meal, containing
75 g carbohydrate, 58 g fat, and 30 g protein to total 1000 kcal.
Calculation of indices of b-cell function and insulin sensitivity
Plasma glucose and insulin concentration during the 150 min of
the LMTT were used to calculate indices of b-cell function and in-
sulin sensitivity as described by Maki et al. [12]. The Matsuda in-
sulin sensitivity index was calculated from fasting glucose (G0) and
insulin (I0) and the respective mean postmeal glucose (Gm) and
insulin (Im) concentrations as 10,000/(G0  I0  Gm  Im)0.5. Beta-
cell function taking the prevailing insulin sensitivity into account
was assessed by the disposition index (LMTT-DI) calculated as total
area under the curve for plasma insulin from 0 to 150 min divided
by the total area under the curve for plasma glucose from 0 to
150 min multiplied by the Matsuda insulin sensitivity index (LMTT-
DI ¼ AUCI/AUCG  Matsuda index) [13].
In comparative analyses, we also evaluated residual b-cell
function from AUC of C-peptide (Cp) and AUC of glucose by
computation of: ((AUCCp/AUCG)  1/fasting Cp), as described by
Bacha et al. [14]. These two measures of b-cell function, LMTT-DI
and the latter index, satisfy the required hyperbolic criteria estab-
lished by Retnakaran et al. [11].
Calculation of indices of glucose proﬁle dynamics
The following indices were calculated from the CGM datasets:
(1) Glucose complexity and autocorrelation function. The short-
term (a1) and long-term (a2) range exponentials were ob-
tained by detrended ﬂuctuation analysis (DFA) according to
Yamamoto et al. [2]. Alpha 1 represents the slope of the
regression within 1.5 h calculated as n ¼ 5e18 points and a2
the slope of the regression over 1.5 h from n¼ 18e576 points.
The autocorrelation function (ACF) coefﬁcient g was calcu-
lated by a decomposition approach of glucose-time series, as
described by Khovanova et al. [3].
(2) Glucose variability. These indices included the mean ampli-
tude of glycemic excursions (MAGE) [15,16] and overall SD
around the sensor-derived mean glucose (SD) [17].
(3) Glucose exposure. The glucose exposure metrics included
mean glucose and percentage time in the glucose target
range (3.9e10.0 mmol/L).
Statistical analyses
We categorized the patients into thirds on the basis of their
disposition index calculated from the liquid meal test. For compar-
ison of continuous variables, we used either one way analysis of
variance (ANOVA) or KruskaleWallis one way analysis, as appro-
priate. Control for multiple comparisons was performed using the
Holm-Sidak and Dunn’s method, respectively. Pearson’s correlation
analysis, linear andnonlinear regressionwere used to relate residual
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ability, and glucose exposure. The stepwise multiple regression
analysis was used to explore the inﬂuence of b-cell function, as
measured by the LMTT-DI (independent variable), on glucose proﬁle
complexity, glycemic variability, glucose exposure, and various
clinical factors (dependent variables). All variables were tested for
normality and, where appropriate, were logarithmically trans-
formed as indicated. p< 0.05was considered statistically signiﬁcant.
To exclude strong interference between independent variables,
collinearity statistics were performed. A variance inﬂation factor
(VIF)  1.40 was found acceptable for inclusion. All statistical ana-
lyses were performed using Statistical Package for the Social Sci-
ences software package (version 17.0; SPSS, Chicago, IL).
Results
Table 1 shows the main characteristics of the study participants
categorized by thirds of themeal test-based disposition index (LMTT-
DI). Duration of diabetes among the LMTT-DI categories was not
signiﬁcantly different in the analysis of variance (p¼ 0.07). The b-cell
functional reserve, including insulin sensitivity, were signiﬁcantly
higher, whereas HbA1c, and fasting plasma glucose values were
lower in the highest than in the two lower thirds of LMTT-DI. Baseline
antihyperglycemic treatment was different among the three cate-
gories. In the top LMTT-DI category, the percentage of patients who
had received diet was 72%, whereas the percentage treated with
sulfonylurea, either alone or in combination with metformin, was
11%. The opposite was true for the lowest category, where 17% of
patients had diet and 72% sulfonylurea alone or in combination with
metformin. All other characteristics, including carbohydrate intake,
did not differ signiﬁcantly across the thirds of LMTT-DI.
Comparisons among the categories for glucose proﬁle
complexity, autocorrelation function, and various glucose metrics
are summarized in Table 2. The data demonstrates that there is an
association between the degree of glucose proﬁle complexity and
b-cell function, as indicated by the DFA short-range and long-rangeTable 1
Main characteristics of patients divided according to thirds of liquid meal tolerance test-
Parameter Thirds of liquid meal tolerance test
1 (<230)
Patients (n) 18
Sex (male/female) 9/9
Age (years) 65.5 (56.0e69.0)
Diabetes duration (years) 9.0 (4.0e11.0)
Body mass index (kg/m2) 29.9  4.3
Systolic blood pressure (mm Hg) 138.1  15.1
Diastolic blood pressure (mm Hg) 82.2  6.7
Carbohydrate intake (g/day) 140  39
Diabetes treatment
Diet alone 3
Sulfonylurea alone 6
Metformin alone 2
Sulfonylurea and metformin 7
Hemoglobin A1C (%) (mmol/mol) 7.5 (6.5e7.7)
58 (48e61)
Fasting plasma glucose (mmol/L) 11.8 (9.0e12.0)
Triglyceride (mmol/L) 2.6 (1.3e3.3)
HDL-cholesterol (mmol/L) 1.1 (1.0e1.3)
Fasting plasma insulin (pmol/L) 114.7 (60.3e166.5)
b-cell function
LMTT-DI (1/mmol2) 102.9 (69.2e166.4)
Insulin sensitivity
Matsuda index (1/pmol  mmol) 3.67 (2.30e5.75)
Data are mean SD, median (25the75th percentile) values or n. The disposition index cat
or the KruskaleWallis one way analysis and Holm-Sidak or Dunn’s test, where appropriat
the <230 disposition index category.
LMTT-DI: liquid meal tolerance test-based disposition index.scaling exponents a, which were found to be smaller in the highest
than in the lowest third of LMTT-DI. No statistically signiﬁcant
difference was documented across the categories for a1 and ACF
exponent g. All mean a2-values were less than 1.5.
Levels for MAGE and SD were lowest in the highest third of the
LMTT-DI, whereas mean glucose diminished when moving from the
lowest to the highest category, indicating that sufﬁciently preserved
b-cell function restrains glucose exposure. Consistently, the percent-
age of values in the target range of 3.9e10.0mmol/L glucose increased
signiﬁcantly with increasing disposition index values; the difference
between the lowest and highest category amounted to 83%.
On Pearson’s correlation analysis (Supplementary Table 1), the
LMTT-DI was signiﬁcantly associated with indices of glucose
complexity and glucose metrics, most strongly with mean glucose
(r ¼ 0.779, p < 0.001), but not with the autocorrelation function.
Though, a strong correlation was found between the ACF exponent
g and DFA exponent a1. Diabetes duration, considered as another
correlate of b-cell function, was included in the correlation analysis.
With the exception of mean glucose, there was no signiﬁcant as-
sociation between diabetes duration and the different characteris-
tics of glycemic stability e the correlation with MAGE slightly
missed the margin of signiﬁcance (p ¼ 0.051). When the relation-
ship between the LMTT-DI and these dynamic indices was then
assessed by regression analysis, signiﬁcant correlations, except for
ACF g, were observed. Associations between the LMTT-DI and DFA
exponents were found to be inverse linear (Fig. 1) with greater
variation at lower disposition index values. Fig. 1A shows the
weaker correlation with a1 (r ¼ 0.277, p ¼ 0.040), whereas the
stronger correlations with a2 (0.441, p < 0.001) is shown in
Fig. 1B. The correlation between the LMTT-DI and ACF g (Fig. 1C)
failed to reach statistical signiﬁcance (r ¼ 0.193, p ¼ 0.163). In
contrast, the association between the LMTT-DI and MAGE, as pre-
sented in Fig. 1D, was curvilinear and stronger (r ¼ 0.625,
p < 0.001) than with the two DFA exponents. A similar regression
curve as with MAGE was found between the LMTT-DI and SD
(r ¼ 0.646, p < 0.001) (data not shown).based disposition index
-based disposition index
2 (230e350) 3 (>350) p value
18 18
8/10 11/7
65.0 (61.0e71.0) 64.5 (63.0e69.0) 0.68
4.5.0 (2.0e9.0) 2.5 (1.0e10.0) 0.07
30.6  3.4 28.9  3.4 0.39
135.3  12.4 134.7  12.7 0.73
82.8  9.1 79.9  5.7 0.48
138  28 134  28 0.87
7 13
5 2
5 3
1 0
6.1 (5.4e6.5)y
43 (36e48)
5.9 (5.5e6.1)*
41 (37e43)
<0.001
7.7 (7.3e8.2)y 6.1 (5.8e7.2)* <0.001
1.6 (1.3e1.9)y 1.8 (1.5e2.1) 0.08
1.3 (1.1e1.5) 1.5 (1.2e1.6)* 0.025
111.6 (96.5e138.0) 90.5 (71.2e100.2) 0.10
254.2 (239.6e284.3)y 467.3 (394.6e547.7)* <0.001
4.72 (3.00e6.00) 6.79 (5.92e9.10)* 0.003
egories are given in 1/mmol2 and were compared using analysis of variance (ANOVA)
e, for multiple comparisons: p < 0.05, * versus the other two categories and y versus
Figure 1. Relationships between the liquid meal tolerance test-based disposition index (LMTT-DI) and (A) DFA exponent a1, (B) DFA exponent a2, (C) AFC exponent g, and (D) mean
amplitude of glycemic excursions (MAGE) in patients with type 2 diabetes. The regression lines were obtained by linear and nonlinear regression equations as indicated for LMTT-DI
versus (A) DFA a1 from a1 ¼ 0.0002 (LMTT-DI) þ 1.8744 (r ¼ 0.277, p ¼ 0.040), (B) DFA a2 from a2 ¼  0.0004 (LMTT-DI) þ 1.3465 (r ¼ 0.441, p < 0.001), (C) ACF g from g ¼ 0.0001
(LMTT-DI) þ 0.1232 (r ¼ 0.193, p ¼ 0.163), and (D) MAGE from MAGE ¼ 1.8713 ln (LMTT-DI) þ 14.9775 (r ¼ 0.625, p  0.001).
Table 2
Comparison of glucose complexity, autocorrelation, glycemic variability, and glucose exposure measures among thirds of residual b-cell function as expressed by the liquid
meal tolerance test-based disposition index
Parameter Thirds of liquid meal tolerance test-based disposition index
1 (<230) 2 (230e350) 3 (>350) p value
Glucose complexity
DFA exponent a1 (<1.5 h) 1.85  0.13 1.84  0.11 1.76  0.12 0.055
DFA exponent a2 (>1.5 h) 1.31  0.13 1.20  0.17y 1.15  0.13* 0.007
Autocorrelation function
ACF exponent g 0.10 (0.06e0.22) 0.13 (0.08e0.26) 0.14 (0.11e0.22) 0.14
Glycemic variability
MAGE (mmol/L) 6.39  1.81 4.48  2.01y 3.33  1.21* <0.001
SD (mmol/L) 2.40  0.68 1.97  0.95 1.32  0.4* <0.001
Glucose exposure
Mean glucose (mmol/L) 13.3 (10.5e14.7) 7.9 (7.2e9.6) 6.6 (6.0e7.3)* <0.001
% time in range 12.0 (3.7e42.3) 86.0 (65.9e94.3)y 94.8 (91.7e99.0)* <0.001
Data are mean SD or median (25the75th percentile) values. Disposition index categories are given in 1/mmol2 and were compared using analysis of variance (ANOVA) or the
KruskaleWallis one way analysis and Holm-Sidak or Dunn’s test, where appropriate, for multiple comparisons: p < 0.05, * versus the other two categories and y versus the
<230 disposition index category.
DFA: detrended ﬂuctuation analysis; a1: short-range scaling exponent; a2: long-range scaling exponent; ACF: autocorrelation function; MAGE: mean amplitude of glycemic
excursion; SD: total SD of all glucose values; % time in range: percentage time of glucose values in range 3.9e10.0 mmol/L.
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Table 3
Results of stepwise forward multiple regression analysis
Dependent variable Explanatory variable Regression
coefﬁcient (b)
SE p value Coefﬁcient of
determination (R2)
DFA exponent a2 LMTT-DI 0.463 0.061 <0.001 0.200
Age 0.286 0.301 0.021 0.281
MAGE LMTT-DI 0.525 0.066 <0.001 0.375
DFA exponent a1 0.324 0.165 0.002 0.483
Male sex 0.236 0.133 0.025 0.538
Hemoglobin A1C LMTT-DI 0.687 0.021 <0.001 0.472
Signiﬁcance level: p < 0.05.
DFA: detrended ﬂuctuation analysis; LMTT-DI: liquid meal tolerance test-based disposition index; MAGE: mean amplitude of glycemic excursions.
LMTT-DI, MAGE, age, and hemoglobin A1C were log-transformed to assure normality.
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assessed by stepwise regression analyses including the LMTT-DI,
Matsuda insulin sensitivity index, DFA short-term scaling expo-
nent a1, age, sex, diabetes duration, and carbohydrate consumption
as the independent variables and the DFA long-range scaling
exponent a2, MAGE, and HbA1c as the dependent variables. The
results of these analyses, provided in Table 3, demonstrate that
the log-transformed LMTT-DI was the strongest independent
contributor to the DFA exponent a2, MAGE, and HbA1c, whereas
age, DFA exponent a1, and male sex, respectively, accounted for
smaller proportions of the variance in these metrics. The other in-
dependent variables above failed to enter the models. When we
used ((AUCCp/AUCG)  1/fasting Cp) as alternative measure of b-cell
function in the stepwise regression models, this variable, similar as
with the LMTT-DI, independently predicted the variance in DFA
exponent a2, MAGE, and HbA1c (b ¼ 0.489, 0.403, and 0.522,
respectively, all p < 0.001).
Two characteristic examples of individual CGM tracings given in
the Supplementary Fig. 1 (A and B) illustrate the close relationship
between residual b-cell function, assessed by the meal-based
disposition index, and glucose proﬁle dynamics. Comparison of
these patterns shows that the high LMTT-DI value (Supplementary
Fig. 1A) was associated with relatively stable and ﬂexible outcomes,
i.e. low MAGE, a2, and ACF g, whereas the low LMTT-DI
(Supplementary Fig. 1B) was related to instability, with higher
values for a2 (lower glucose complexity), MAGE and ACF g than for
those in example A. Of note, although the HbA1c values were
virtually identical in these samples, the pattern dynamics were
remarkably different.
Discussion
Our results support the hypothesis that residual b-cell function
assessed by the LMTT-based disposition index has a substantial
impact on CGM proﬁle dynamics. We observed a signiﬁcant
decline in complexity and levels of glucose metrics concomitant
with an increase of glucose readings in the target range across
rising categories of the LMTT-DI. While glycemic variability and
mean glucose decreased by roughly 50% from the lowest to the
highest category, the percentage of glucose values in the target
range increased by 81%. We further show that the relationships
between b-cell function and glucose complexity factors are in-
verse linear, whereas those with glucose metrics, exempliﬁed by
the regression curve for MAGE and LMTT-DI, are curvilinear.
Consistent with our ﬁndings, Chen et al. [18] observed hyperbolic
relationships between glycemic variability indices and the DI ob-
tained from an oral glucose test across various stages of glucose
intolerance. The curvilinear relationship between glycemic vari-
ability and the LMTT-DI implies that the better the b-cell function,
the better the glycemic stability (lower glycemic variability). It
further indicates that a decline of more than 50% b-cell function isrequired for chronic dysregulation of glycemia to occur. This is
compatible with the UKPDS outcomes [19] and our sample CGM
tracings (Supplementary Fig. 1). Comparison of these two patient
samples shows that, along with the drastic reduction of b-cell
function (LMTT-DI), the glucose proﬁles became remarkably
different both in appearance and with regard to the dynamic
parameters.
As the multivariate regression analyses clearly demonstrate, the
LMTT-DI is an independent predictor of glucose complexity, gly-
cemic variability, and glycemic exposure as well, explaining 20, 38,
and 47% of the variance in DFA long-range scaling exponent a2,
MAGE, and HbA1c, respectively. The short-range scaling exponent
a1, age, and male sex contribute an additional 9 e 6% to the change
in a2 and MAGE. Insulin sensitivity, as measured by the Matsuda
index, was not associated with variations in the glucose proﬁle
dynamics. This may be attributable to a predominant pathogenic
role of b-cell function at the stage of overt type 2 diabetes [20,21].
The inﬂuence of baseline antidiabetic therapy could be neglected in
these models since the relevant variables were determined during
withdrawal of oral drugs. Genetic [22] as well as environmental
factors [23] or hyperglycemic hormones may be responsible for the
residual amount of unexplained variance in the dependent vari-
ables. However, their inﬂuence is difﬁcult to assess in a retrospec-
tive analysis for which the primary goal was to investigate the
contribution of b-cell function to CGM measures. It should also be
noted that the category with the lowest insulin secretion capacity
(LMTT-DI < 230), including the highest proportion of patients who
had received treatment (prior to withdrawal) with sulfonylurea
either alone or combined with metformin, was characterized by
comparatively long diabetes duration, elevated HbA1c and fasting
plasma glucose, and diminished HDL-cholesterol levels. The higher
fasting glucose levels found in this group compared to the other
two groups with higher LMTT-DI values may be partly due to
discontinuation of OHA for 8 days. Even short-term moderate hy-
perglycemia has been shown to be detrimental [5,6], and exposure
to elevated fasting glucose is likely to aggravate the prevailing de-
fects in b-cell function.
Overall, the present paper contributes to the discussion of the
natural history of glycemic dysregulation. The fact that insulin is
known to prevent b-cell defects [24] by reduction of glucolipotoxicity
[25,26] and inhibitory effects on oxidative stress, as recently shown
by Monnier et al. [27] has led to assume that early insulin therapy
might be an option to slow down loss of b-cell function. However, the
question whether early treatment with insulin [28e30] can really
provide b-cell protection, is not clearly established and requires
long-term clinical studies. As pointed out by Del Prato and coauthors
[31], any treatment capable of correcting the pathogenetic b-cell
abnormalities should ensure glycemic stability. In this context, the
proposal by DeFronzo et al. [32] to initiate a triple therapy with
antidiabetic agents at the earliest stage of the disease,might preserve
b-cell health better than customary approaches.
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spective nature and the use of a surrogate measure as estimate of
pancreatic b-cell function. Nevertheless, among the several indices,
the LMTT-DI is a validated, widely accepted measure, taking into
account the degree of the patient’s insulin sensitivity [12,13]. Pre-
viously, we used b-cell function parameters derived from an insulin
secretion model [8] that did not account for insulin resistance. In
the present work, we have used LMTT-DI and mentioned as alter-
native a functional parameter ((AUCCp/AUCG)  1/fasting Cp) that is
based on measurement of C-peptide plasma concentrations. It has
been claimed that plasma C-peptide more accurately than insulin
levels reﬂects b-cell function [33]. The advantage of measuring C-
peptide is that it is cleared in peripheral tissue at a rather constant
rate, and it escapes hepatic degradation. Despite the differential
kinetics of insulin and C-peptide, our results obtained in the step-
wise regression analyses when using either LMTT-DI or (AUCCp/
AUCG)  1/fasting Cp, were comparable. The strength of the
investigation is that both glucose proﬁle characteristics and the
index of b-cell function were assessed during oral drug withdrawal
to largely exclude therapeutic inﬂuences. Patients taking TZDs had
been excluded, because of long duration of effect after withdrawal.
In summary, we demonstrate the existence of close inverse
linear and curvilinear relationships between dynamic glucose
proﬁle characteristics and b-cell dysfunction in non-insulin treated
patients with type 2 diabetes. Deterioration in glucose dynamics is
partly a reﬂection of the defective b-cell; however, variability
metrics such as MAGE are more strongly affected by the residual
b-cell function than those of intrinsic dynamics such as long-range
negative correlation. The missing correlation between the ACF
exponent and the LMTT-DI indicates that linear predictability of
glucose is independent of the residual b-cell function. Our results
further support the view that maintaining residual b-cell function is
most important to prevent derangement of glucose dynamics.
Clinical trials are necessary to clarify whether therapies targeted at
b-cell status may reduce decomplexiﬁcation and variability in gly-
cemic proﬁles and thus improve diabetes control.
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Supplementary Figure 1. Sample continuous glucose monitoring tracings obtained
from two patients with type 2 diabetes. Gender, age, diabetes duration, body mass
index, HbA1c values, mean glucose, and antihyperglycemic therapy were (A) male, 63
years, 10 years, 29.4 kg/m2, 6.6%, 6.5 mmol/L, and diet; (B) female, 69 years, 11 years,
23.4 kg/m2, 6.5%, 12.4 mmol/L, and sulfonylurea plus metformin. The changes in re-
sidual ß-cell function, as measured by the disposition index (LMTT-DI) derived from
the liquid meal tolerance test, DFA exponent a1 and a2, ACF g, and glucose variability
(MAGE) corresponding to the patterns of glucose tracings are shown in the table
beneath. The dashed horizontal lines (blue) denote the target range (3.9e10.0 mmol/L).
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Supplementary Table 1
Correlation matrix for b-cell function as measured by the liquid meal tolerance test-based disposition index and different characteristics of glycemic stability
LMTT-DI Diabetes duration DFA exponent a1 DFA exponent a2 ACF coefﬁcient g SD MAGE Mean glucose HbA1c
LMTT-DI 1
Diabetes duration 0.23 1
DFA exponent a1 0.275* 0.04 1
DFA exponent a2 0.437y 0.24 0.07 1
AFC coefﬁcient g 0.18 0.08 0.724y 0.05 1
SD 0.601y 0.23 0.400* 0.578y 0.22 1
MAGE 0.597y 0.269 0.416* 0.583y 0.24 0.923y 1
Mean glucose 0.779y 0.480y 0.18 0.470* 0.16 0.638y 0.638y 1
HbA1c 0.580y 0.25 0.06 0.397* 0.10 0.453y 0.393* 0.673y 1
The Pearson correlation coefﬁcients (r) are shown. p values (two-sided) are *<0.01 and y<0.001. ACF: autocorrelation function; DFA: detrended ﬂuctuation analysis; LMTT-DI:
liquid meal tolerance test-based disposition index; MAGE: mean amplitude of glycemic excursions; SD: standard deviation of mean glucose.
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